Moneycontrol PRO
Open App

Bharat Biotech's Covaxin found to be safe, induced immune response in Phase-1

The overall incidence of 'adverse events' was 14–21 percent in all vaccine-treated groups, says the data published in Lancet. The company says the incidence of adverse events are noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.

January 22, 2021 / 04:15 PM IST

Bharat Biotech's coronavirus vaccine Covaxin has been found to be well-tolerated and produced an immune response, says the Phase-1 interim data published by the company in the peer-reviewed British medical journal Lancet.

The findings come at a time amid reports that some healthcare workers, including doctors, were not turning up to take the indigenously developed jab, which was given the emergency approval under the "trial mode", over safety concerns.  India rolled out its vaccination drive on January 16 and will innoculate frontline workers first.

In Phase-1, potential vaccines are tested on healthy human volunteers to check for the safety or potential side-effects of the vaccine and the immunogenicity, or the immune response that enables the body to fight an infection.

Covaxin has been developed by the Hyderabad-based biotechnology firm in collaboration with the Indian Council of Medical Research and the National Institute of Virology. The vaccine is now undergoing phase-3 trials. Phase 2 trials are being analysed.

Also read: Healthcare workers feel used as ‘guinea pigs’, hesitate to take Covaxin: Report


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Bharat Biotech conducted the Phase-1 study between July 13 and 30, 2020. The company said it screened 897 individuals but ended up enrolling 375. The participants were between 18 and 55 years of age.

The duration of the study is 12 months, which means that all the participants will be followed-up during this period.

The most common adverse event was pain at the injection site followed by headache, fatigue, and fever, the study said.

The overall incidence of solicited local and systemic adverse events in this study was 14–21 percent in all vaccine-treated groups. The company said the incidence of adverse events were noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

Among the enrolled participants, 100 each were randomly assigned to the three vaccine groups and 75  to the control group (Algel only).

After both doses, solicited local and systemic adverse reactions were reported by 17 percent participants in the 3 µg with Algel-IMDG group, 21 percent in the 6 µg with Algel-IMDG group, 14 in the 6 µg with Algel group, and ten in the Algel-only group. Five percent participants complained of pain at the injection site. Headache and fatigue were reported by 3 percent, while fever and nausea in 2 percent.

Algel and IMDG are adjuvants that help to boost the vaccine efficacy.

Of the adverse events, 69 percent were mild and 31 percent moderate. These were more frequent after the first dose.

One serious adverse event of viral pneumonitis was reported in the 6 µg with Algel group, unrelated to the vaccine, the study said.

Immune response

According to the study, Covaxin has induced binding and neutralising antibody responses. On Day 28 or 14 days after the second dose, all subjects who received the vaccine intramuscularly had significantly elevated spike binding IgG antibodies and neutralising antibody titers.

The inclusion of the Algel-IMDG adjuvant helped the vaccine to induce a Th1-biased response or T-Cell response, that provides adaptive immunity.

The vaccine has been approved for restricted emergency use under clinical trial mode. The government has procured 55 million doses of the vaccine, and has begun vaccination rollout.
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jan 22, 2021 12:43 pm
ISO 27001 - BSI Assurance Mark